(Q43645570)

English

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses

scientific article published on 29 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

Philippe Flandre

11

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Anne-Geneviève Marcelin

14

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

author name string

S Lambert-Niclot

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

C Charpentier

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

A Storto

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

D B Fofana

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

C Soulié

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

S Fourati

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

B Visseaux

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

M Wirden

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

L Morand-Joubert

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

B Masquelier

10

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

V Calvez

12

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

D Descamps

13

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

29 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

68

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1237-1242

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT003

21 January 2018

Identifiers

10.1093/JAC/DKT003

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43645570&oldid=2102293306"